Tumor-targeted and activated bioconjugates for improved camptothecin delivery

Anti-Cancer Drugs

Volumn 16, Issue 7, 2005, Pages 763-775

  Paranjpe, Pankaj V ^a   Stein, Stanley ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Camptothecin; Polyethylene glycol conjugate; Receptor mediated endocytosis; Site specific delivery; Syngeneic model

Indexed keywords

ALANINE; AMINO ACID DERIVATIVE; CAMPTOTHECIN; CATHEPSIN B; FOLATE RECEPTOR; FOLIC ACID; GLYCINE; MACROGOL; PHENYLALANINE; PROLINE;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; ENZYME MECHANISM; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; RAT; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TUMOR VOLUME;

AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CATHEPSIN B; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ESTERS; FEMALE; FOLIC ACID; HUMANS; HYDROLYSIS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED F344; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 23344444244     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000172834.78068.7c     Document Type: Article

References (38)

1. Saetern A, Brandi M, Bakkelund WH, Sveinbjornsson B. Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 2004; 15:899-906.
2. Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res 2002; 19:1389-1399.
3. Minko T, Paranjpe PV, Qiu B, Lalloo A, Won R, Stein S, et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multi-drug resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 2002; 50:143-150.
4. Paranjpe PV, Chen Y, Kholodovych V, Welsh W, Stein S, Sinko PJ. Tumor-targeted bioconjugates based delivery of camptothecin: design, synthesis and in vitro evaluation. J Controlled Rel 2004; 100:275-292.
5. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000; 1477:98-111.
6. Tung C, Bredow S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconj Chem 1999; 10:892-896.
7. Putnam DA, Shiah J, Kopecek J. Intracellularly biodegradable derivatives of 5-fluorouracil. Biochem Pharmacol 1996; 52:957-962.
8. March J. Advanced Organic Chemistry. New York: Wiley; 1995.
9. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002; 54:675-693.
10. Greenwald RB. PEG drugs: an overview. J Controlled Rel 2001; 74:159-171.
11. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. Proc Natl Acad Sci USA 1994; 269:3198-3204.
12. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release from T-1028, camptothecin analogue-carboxymethyl dextran conjugate. J Controlled Rel 2000; 69:399-412.
13. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57:3585-3593.
14. Conover CD, Greenwald RB, Pendri A, Shum KL. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des 1999; 14:499-506.
15. Putnam DA, Kopecek J. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. Bioconj Chem 1995; 6:483-492.
16. Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconj Chem 1998; 9:618-626.
17. Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000; 1477:215-230.
18. Buchwald P, Bodor N. Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters. Pharmazie 2002; 57:87-93.
19. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters, J Med Chem 1999; 42:5160-5168.
20. Buchwald P. Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 2001; 1:101-111.
21. Aronov O, Horowitz AT, Gabizon A, Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconj Chem 2003; 14:563-574.
22. Li S, Deshmukh HM, Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res 1998; 15:1540-1544.
23. 10 enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J Org Chem 2001; 66:5655-5663.
24. Quintana A, Raczka E, Pielher L, Lee I, Myc A, Majoras I, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002; 19:1310-1316.
25. Shinoda T, Takagi A, Maeda A, Kagatani S, Konno Y, Hashida M. In vivo fate of folate-BSA in non-tumor and tumor-bearing mice. J Pharm Sci 1998; 87:1521-1526.
26. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003; 9:6551-6559.
27. Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 2003; 20:417-422.
28. Quo Y, Mazar A, Lebrun J, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 2002; 62:4678-4684.
29. Ma JL. Autologous Tumor Vaccination. Piscataway, NJ: Rutgers, State University of New Jersey; 2002.
30. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, et al. Complete regression of xenografted human carcinomas by camptothecin analog-carboxymethyl dextran conjugate (T-0128). Cancer Res 2000; 60:2988-2995.
31. Lerchen HG, Baumgarten J, von dem Bruch K, Lehmann TE, Sperzel M, Kempka G, et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 2001; 44:4186-4195.
32. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 1994; 73:2432-2443.
33. Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla J, Shih C, et al. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enz Reg 1996; 36:365-381.
34. 111In-DTPA-methotrexate. Cancer Biother Radiopharm 1998; 13:177-184.
35. Islam I, Ng K, Chong KT, McQuade TJ, Hui JO, Wilkinson KF, et al. Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors. J Med Chem 1994; 37:293-304.
36. Na K, Lee N, Park KH, Shin EK, Lee YB, Choi HK. Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur J Pharm Sci 2003; 18:165-173.
37. Greenwald RB, Pendri A, Conover CD, Lee C, Choe YH, Gilbert C, et al. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg Med Chem 1998; 6:551-562.
38. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002; 28(suppl):A13-A16.